A Phase 2 interventional study of MB-102-- single dose of 4 µmol/kg and MB-102-- single dose of 130 mg in Acute Kidney Injury, sponsored by MediBeacon. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-26.
Sponsored by MediBeacon · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.
Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 66th largest by enrollment of the 237 interventional ones that give a count, is one of 18 that started in 2016, is one of 54 in phase 2, and was the 147th registered.
1,691 studies on the registry are indexed under Acute Kidney Injury; 393 are open to participants now.
Browse Acute Kidney Injury studies →72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 30–75
Massachusetts General Hospital · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
Bassett Healthcare · Sites in United States
Ages 18+
Dana Fuhrman · Sites in United States
Ages up to 18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 230 Acute Kidney Injury studies recruiting now, 162 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
370 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 69 · Phase 3 29 · Phase 4 23
First in 1999; this study’s year is marked. 18 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 234 is above the median of 100 across 817 interventional studies indexed under Acute Kidney Injury.
Median enrollment 67 across the 237 interventional studies, 124 across the 131 observational. Of the 240 that completed or were terminated, 84 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 370 have an industry lead sponsor. The 10 most frequent:
MediBeacon is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
MediBeacon has 4 studies filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
33 of the studies in Acute Kidney Injury with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161843Phase 3Ebima Clifford OkundayeUse of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF) | 2026-12-30 |
| NCT05399537Phase 3Vantive Health LLCSafety Evaluation of Prismocitrate 18 in Patients Receiving CRRT | 2027-01 |
| NCT05084196Phase 3Rutgers, The State University of New JerseyMelatonin for Prevention of Kidney Injury | 2027-06-01 |
| NCT07001098Stanford UniversityAmino Acids for Cardiac Surgery Associated AKI | 2026-11 |
| NCT07016074University of MichiganInorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury | 2026-11-30 |
Add all 33 to your calendar (.ics) → With an account.
Among the 370 studies in Acute Kidney Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was a pilot, safety, and pharmacokinetic study of MB-102 versus iohexol and the use of the non-invasive optical renal function monitor (ORFM) device in normal and compromised renal function participants with different skin color types.
The objectives of this study were to evaluate the safety and tolerability of single and multiple doses of MB-102 in participants with normal and impaired kidney function; to determine plasma pharmacokinetics of MB-102 compared to the pharmacokinetics of iohexol in participants with normal and impaired kidney function; to demonstrate that MB-102-transdermal-fluorescence-measured glomerular filtration rate (GFR) using the optical renal function monitor (ORFM) Brilliance device is aligned with MB-102 plasma GFR; to evaluate the safety and effectiveness of the ORFM investigational medical device prototypes QuantumLeap, Radiance, and Brilliance for the non-invasive transdermal fluorescent detection of MB-102 in participants with a range of skin color types; and to determine the optimal dose of MB-102 for non-invasive measurement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Main Criteria for Inclusion (Quantum Leap and Radiance device)
Age > 22 years - male or female
Main Criteria for Inclusion (Brilliance device)
Age > 18 years - male or female
Normal-CKD Stage 2/QuantumLeap; Normal-CKD Stage 2/Radiance; Normal-CKD Stage 2/Brilliance algorithm optimization; Normal-CKD Stage 2/Brilliance sensor optimization; Normal-CKD Stage 2/Brilliance sensor optimization; and Normal-CKD Stage 2/Brilliance (1-2 sensors)
CKD Stage 3-4/QuantumLeap
Stable use of medications (when applicable)
CKD Stage 3-5/Radiance; CKD Stage 3-5/Brilliance algorithm optimization; CKD Stage 3-5/Brilliance sensor validation; and CKD Stage 3-5/Brilliance 1-2 sensors
EXCLUSION CRITERIA
Main Criteria for Exclusion (QuantumLeap device)
Additional Exclusion: Normal-CKD Stage 2/QuantumLeap
Additional Exclusion: CKD Stage 3-4/QuantumLeap
Main Criteria for Exclusion: (Radiance device)
Women who are pregnant, lactating or planning to become pregnant during the study, or women who are of childbearing potential unwilling to use a barrier method of birth control
o Males must be willing to practice abstinence or utilize adequate contraception from dosing day to at least 7 days post dose
Main Criteria for Exclusion: (Brilliance device)
Women who are pregnant, lactating or planning to become pregnant during the study, or women who are of childbearing potential unwilling to use a barrier method of birth control
o Males must be unwilling to practice abstinence or utilize adequate contraception from dosing day to at least 7 days post dose
Additional Exclusion: Normal-CKD Stage 2/Radiance; Normal-CKD Stage 2/Brilliance algorithm optimization; Normal-CKD Stage 2/Brilliance sensor optimization; Normal-CKD Stage 2/Brilliance sensor validation; and Normal-CKD Stage 2/Brilliance (1-2 sensors)
Additional Exclusion: CKD Stage 3-5/Radiance; CKD Stage 3-5/Brilliance algorithm optimization; CKD Stage 3-5/Brilliance sensor validation; and CKD Stage 3-5/Brilliance 1-2 sensors
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MB-102 and iohexol administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the QuantumLeap ORFM device. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. In order to determine the optimal dose of MB-102, participants may have received different doses.
Drug: MB-102-- single dose of 4 µmol/kg · Drug: Iohexol · Device: QuantumLeap
MB-102 and iohexol administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-4), and fluorescence measured by the QuantumLeap ORFM device. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. In order to determine the optimal dose of MB-102, participants may have received different doses.
Drug: MB-102-- single dose of 4 µmol/kg · Drug: Iohexol · Device: QuantumLeap
MB-102 and iohexol administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Radiance ORFM device. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
Drug: MB-102-- single dose of 4 µmol/kg · Drug: Iohexol · Device: Radiance
MB-102 and iohexol administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Radiance ORFM device. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
Drug: MB-102-- single dose of 4 µmol/kg · Drug: Iohexol · Device: Radiance
MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Algorithm optimization of the Brilliance sensor was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
Drug: MB-102-- single dose of 4 µmol/kg · Device: Brilliance (1 or 2 sensors)
MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. Algorithm optimization of the Brilliance sensor was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
Drug: MB-102-- single dose of 4 µmol/kg · Device: Brilliance (1 or 2 sensors)
MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Sensor optimization of the Brilliance device was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
Drug: MB-102-- single dose of 4 µmol/kg · Device: Brilliance (1 or 2 sensors)
MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Validation of the Brilliance sensor was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
Drug: MB-102-- single dose of 4 µmol/kg · Device: Brilliance (1 or 2 sensors)
MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. Validation of the Brilliance sensor was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
Drug: MB-102-- single dose of 130 mg · Device: Brilliance (1 or 2 sensors)
MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device (1-2 sensors). The optimized algorithm and final device design of the Brilliance device was tested. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. A subset of participants in this arm received two doses of MB-102, 12 hours apart.
Drug: MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart · Device: Brilliance (1 or 2 sensors)
MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device (1-2 sensors and 2-part sensor). The optimized algorithm and final device design of the Brilliance device was tested. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. A subset of participants in this arm received two doses of MB-102, 12 hours apart.
Drug: MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart · Device: Brilliance (1 or 2 sensors) · Device: Brilliance (2-part sensor)
Two doses of MB-102 administered to participants 12 hours apart, with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device (1-2 sensors and 2-part sensor). The optimized algorithm and final device design of the Brilliance device was tested. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
Drug: MB-102-- two doses of 130 mg 24 hours apart · Device: Brilliance (1 or 2 sensors) · Device: Brilliance (2-part sensor)
MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. The optimized algorithm and final device design of the Brilliance device was tested. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
Drug: MB-102-- single dose of 130 mg · Device: Brilliance (1 or 2 sensors)
Drug page: Relmapirazin
4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
Also known as: Relmapirazin
130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
Also known as: Relmapirazin
130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
Also known as: Relmapirazin
4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
Also known as: Relmapirazin
5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds
Also known as: Omnipaque 300
Optical Renal Function Monitor (ORFM)
Optical Renal Function Monitor (ORFM)
Optical Renal Function Monitor (ORFM)
Optical Renal Function Monitor (ORFM)
Number of Participants With Treatment-Emergent Adverse Events
An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.
Time frame: From the time of dosing through the follow-up visit, up to 10 days
Maximum Plasma Concentration (Cmax) of MB-102
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. Maximum plasma concentration (Cmax; measured in ng/mL) was directly determined from the concentration-time data.
Time frame: Pre-dose and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose.
Maximum Plasma Concentration (Cmax) of Iohexol
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. Maximum plasma concentration (Cmax; measured in ng/mL) was directly determined from the concentration-time data.
Time frame: Pre-dose and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose.
Time to Maximum Plasma Concentration (Tmax) of MB-102
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The time to maximum plasma concentration (Tmax; measured in minutes) was directly determined from the concentration-time data.
Time frame: Pre-dose and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose.
Time to Maximum Plasma Concentration (Tmax) of Iohexol
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The time to maximum plasma concentration (Tmax; measured in minutes) was directly determined from the concentration-time data.
Time frame: Pre-dose and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose.
The Elimination Half-life of MB-102
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The elimination half-life (the time required for the concentration of the drug to reach half of its original value) was calculated as t1/2 λz= ln(2)/ λz.
Time frame: Pre-dose and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose.
The Elimination Half-life of Iohexol
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The elimination half-life (the time required for the concentration of the drug to reach half of its original value) was calculated as t1/2 λz= ln(2)/ λz.
Time frame: Pre-dose and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose.
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration for MB-102
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The area under the plasma concentration-time curve (ng\*min/mL) was be estimated from time 0 to the last measurable concentration using noncompartmental analyses.
Time frame: Pre-dose and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose.
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration for Iohexol
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The area under the plasma concentration-time curve (ng\*min/mL) was be estimated from time 0 to the last measurable concentration using noncompartmental analyses.
Time frame: Pre-dose and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose.
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity for MB-102
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The area under the plasma concentration-time curve (ng\*min/mL) from time 0 to infinity was calculated as: AUC∞ = AUClast + LQC/λz where LQC is the predicted concentration (based on the terminal regression) at the time of the last measurable concentration.
Time frame: Pre-dose and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose.
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity for Iohexol
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The area under the plasma concentration-time curve (ng\*min/mL) from time 0 to infinity was calculated as: AUC∞ = AUClast + LQC/λz where LQC is the predicted concentration (based on the terminal regression) at the time of the last measurable concentration.
Time frame: Pre-dose and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose.
Total Plasma Clearance of MB-102
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. Total plasma clearance (the volume of plasma cleared of the drug over time) was calculated as: Clp = Dose/ AUC∞.
Time frame: Pre-dose and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose.
Total Plasma Clearance of Iohexol
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. Total plasma clearance (the volume of plasma cleared of the drug over time) was calculated as: Clp = Dose/ AUC∞.
Time frame: Pre-dose and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose.
The Terminal Rate Constant for MB-102
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The terminal rate constant (λz) was determined by linear regression of the terminal linear phase of the log plasma concentration-time profile.
Time frame: Pre-dose and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose.
The Terminal Rate Constant for Iohexol
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The terminal rate constant (λz) was determined by linear regression of the terminal linear phase of the log plasma concentration-time profile.
Time frame: Pre-dose and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose.
Renal Clearance of MB-102
Urine samples were collected pre-dose (time 0) and 5 mL urine samples were collected each time the subject voided. The total volume of urine excreted was recorded until 12 hours post-dose, and was analyzed using validated analytical methods. Renal clearance (the volume of plasma cleared of the drug by the kidneys over time) was calculated as: CLr = Ae/ AUClast, where Ae is the cumulative amount of analyte excreted in urine over the sampling interval.
Time frame: Pre-dose and each time the participant voids up to 720 minutes post dose
Renal Clearance of Iohexol
Urine samples were collected pre-dose (time 0) and 5 mL urine samples were collected each time the subject voided. The total volume of urine excreted was recorded until 12 hours post-dose, and was analyzed using validated analytical methods. Renal clearance (the volume of plasma cleared of the drug by the kidneys over time) was calculated as: CLr = Ae/ AUClast, where Ae is the cumulative amount of analyte excreted in urine over the sampling interval.
Time frame: Pre-dose and each time the participant voids up to 720 minutes post dose
Correlation Between the Transdermal Fluorescence Intensity of MB-102 as Measured by the Quantum Leap Device and Plasma Concentration of MB-102 at Each Time Point in the Renal Excretion Phase
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. Transdermal fluorescence intensity at the time of blood sampling as measured by the QuantumLeap device was documented, and the correlation between the transdermal fluorescence intensity of MB-102 as measured by the QuantumLeap device and the plasma concentration of MB-102 at each time point in the renal excretion phase was calculated.
Time frame: Pre-dose (time 0) and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose
Correlation Between the Transdermal Fluorescence Intensity of MB-102 as Measured by the Radiance Device and Plasma Concentration of MB-102 at Each Time Point in the Renal Excretion Phase
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and will be analyzed using validated analytical methods. Transdermal fluorescence intensity at the time of blood sampling as measured by the Radiance device was documented, and the correlation between the transdermal fluorescence intensity of MB-102 as measured by the Radiance device and the plasma concentration of MB-102 at each time point in the renal excretion phase was calculated.
Time frame: Pre-dose (time 0) and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose
Correlation Between the Transdermal Fluorescence Intensity of MB-102 as Measured by the Brilliance Device and Plasma Concentration of MB-102 at Each Time Point in the Renal Excretion Phase in Participants With Normal-CKD Stage 2 Renal Function
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, and 480 minutes post dose, and were analyzed using validated analytical methods. Transdermal fluorescence intensity at the time of blood sampling as measured by the Brilliance device was documented, and the correlation between the transdermal fluorescence intensity of MB-102 as measured by the Brilliance device and the plasma concentration of MB-102 at each time point in the renal excretion phase was calculated.
Time frame: Pre-dose (time 0) and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, and 480 minutes post dose
Correlation Between the Transdermal Fluorescence Intensity of MB-102 as Measured by the Brilliance Device and Plasma Concentration of MB-102 at Each Time Point in the Renal Excretion Phase in Participants With CKD Stage 3-4 Renal Function
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) and 960, 1440, 1920, 2400, and 2880 (±30 min) minutes post dose, and were analyzed using validated analytical methods. Transdermal fluorescence intensity at the time of blood sampling as measured by the Brilliance device was documented, and the correlation between the transdermal fluorescence intensity of MB-102 as measured by the Brilliance device and the plasma concentration of MB-102 at each time point in the renal excretion phase was calculated.
Time frame: Pre-dose (time 0) and 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) and 960, 1440, 1920, 2400, and 2880 (±30 min) minutes post dose
Number of Participants With Adverse Events Related to the Use of the QuantumLeap Device
The number of participants with adverse events related to the use of the QuantumLeap device was documented.
Time frame: From the time of dosing through the follow-up visit, up to 10 days
Number of Participants With Adverse Events Related to the Use of the Radiance Device
The number of participants with adverse events related to the use of the Radiance device was documented.
Time frame: From the time of dosing through the follow-up visit, up to 10 days
Number of Participants With Adverse Events Related to the Use of the Brilliance Device
The number of participants with adverse events related to the use of the Brilliance device was documented.
Time frame: From the time of dosing through the follow-up visit, up to 10 days
| Milestone | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 31 | 29 | 20 | 40 | 9 | 7 | 18 | 30 | 18 | 12 | 4 | 4 | 12 |
| Completed | 31 | 29 | 20 | 40 | 9 | 7 | 17 | 29 | 18 | 12 | 4 | 4 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.
| Participants | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events | 7 | 7 | 2 | 1 | 1 | 1 | 2 | 0 | 1 | 2 | 1 | 1 | 2 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. Maximum plasma concentration (Cmax; measured in ng/mL) was directly determined from the concentration-time data.
| ng/mL | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of MB-102 | 10751.613 ± 2279.3699 | 11625.517 ± 2491.4304 | 11981.7 ± 2659.9568 | 12243.45 ± 2563.5734 | 13961.111 ± 3326.5064 | 14440.143 ± 3049.767 | 13747.739 ± 2985.4673 | 13453.74 ± 3886.9335 | 13039.944 ± 3819.8448 | 13015.833 ± 2314.2462 | 15650 ± 4023.6799 | 13125 ± 2818.2441 | 11665 ± 3637.8803 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. Maximum plasma concentration (Cmax; measured in ng/mL) was directly determined from the concentration-time data.
| ng/mL | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Iohexol | 295967.742 ± 71088.9039 | 290172.414 ± 74285.6788 | 333000 ± 70799.9405 | 329200 ± 98658.229 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The time to maximum plasma concentration (Tmax; measured in minutes) was directly determined from the concentration-time data.
| minutes | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of MB-102 | 7.258 ± 5.2976 | 5.862 ± 2.341 | 5.25 ± 1.118 | 5.875 ± 2.2325 | 5 ± 0 | 6.429 ± 2.4398 | 6.111 ± 2.7416 | 5.167 ± 0.9129 | 12.222 ± 27.0197 | 5 ± 0 | 5 ± 0 | 5 ± 0 | 25 ± 67.7227 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The time to maximum plasma concentration (Tmax; measured in minutes) was directly determined from the concentration-time data.
| minutes | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance |
|---|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Iohexol | 9.194 ± 5.338 | 7.069 ± 3.1388 | 6.5 ± 2.3508 | 6.875 ± 2.7003 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The elimination half-life (the time required for the concentration of the drug to reach half of its original value) was calculated as t1/2 λz= ln(2)/ λz.
| minutes | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| The Elimination Half-life of MB-102 | 130.712 ± 33.5894 | 314.267 ± 151.5375 | 135.821 ± 26.0772 | 301.21 ± 183.0147 | 123.681 ± 25.4325 | 245.7 ± 51.3774 | 140.176 ± 22.2139 | 122.86 ± 14.6245 | 305.944 ± 105.6855 | 126.049 ± 20.65 | 147.117 ± 23.779 | 127.842 ± 22.9881 | 440.488 ± 294.5741 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The elimination half-life (the time required for the concentration of the drug to reach half of its original value) was calculated as t1/2 λz= ln(2)/ λz.
| minutes | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance |
|---|---|---|---|---|
| The Elimination Half-life of Iohexol | 148.056 ± 38.2236 | 366.529 ± 191.4136 | 151.776 ± 31.4044 | 347.574 ± 214.8895 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The area under the plasma concentration-time curve (ng\*min/mL) was be estimated from time 0 to the last measurable concentration using noncompartmental analyses.
| ng*min/mL | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration for MB-102 | 1131336.448 ± 254801.4255 | 2419911.379 ± 708114.7104 | 1211931.882 ± 296491.1469 | 2467846.174 ± 843410.9665 | 1121973.694 ± 190118.8591 | 2560133.925 ± 519858.5738 | 1235178.035 ± 310587.5336 | 1072786.062 ± 281421.3481 | 2476458.456 ± 543445.259 | 1384887.303 ± 345784.1469 | 1488269.994 ± 108723.6082 | 1316506.556 ± 314196.0436 | 3678411.381 ± 1344727.8138 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The area under the plasma concentration-time curve (ng\*min/mL) was be estimated from time 0 to the last measurable concentration using noncompartmental analyses.
| ng*min/mL | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance |
|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration for Iohexol | 33329159.548 ± 7909842.8639 | 58097567.569 ± 15177720.419 | 36677146.278 ± 10789963.956 | 70005450.758 ± 30243153.821 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The area under the plasma concentration-time curve (ng\*min/mL) from time 0 to infinity was calculated as: AUC∞ = AUClast + LQC/λz where LQC is the predicted concentration (based on the terminal regression) at the time of the last measurable concentration.
| ng*min/mL | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity for MB-102 | 1166655.776 ± 298807.3587 | 3212036.698 ± 1490329.1808 | 1242760.175 ± 321230.0672 | 3045719.769 ± 1625406.4454 | 1182254.364 ± 208571.1669 | 2914852.088 ± 684490.5106 | 1264462.94 ± 333601.038 | 1086390.141 ± 287588.9895 | 3135394.594 ± 1051071.597 | 1403855.606 ± 355269.4445 | 1518516.431 ± 106177.2201 | 1340051.2 ± 332392.6494 | 3844963.027 ± 1630799.1909 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The area under the plasma concentration-time curve (ng\*min/mL) from time 0 to infinity was calculated as: AUC∞ = AUClast + LQC/λz where LQC is the predicted concentration (based on the terminal regression) at the time of the last measurable concentration.
| ng*min/mL | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance |
|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity for Iohexol | 34688858.452 ± 9029243.5529 | 81061044.851 ± 37977572.641 | 38032869.839 ± 11788838.136 | 90107803.206 ± 61220389.979 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. Total plasma clearance (the volume of plasma cleared of the drug over time) was calculated as: Clp = Dose/ AUC∞.
| mL/minute | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Plasma Clearance of MB-102 | 110.719 ± 28.2476 | 51.741 ± 21.4424 | 102.361 ± 31.8835 | 51.322 ± 26.2932 | 103.107 ± 17.1532 | 44.677 ± 13.798 | 97.496 ± 18.6913 | 117.913 ± 39.4472 | 42.838 ± 13.1284 | 99.216 ± 33.0196 | 84.29 ± 5.0376 | 97.741 ± 23.5163 | 38.736 ± 13.87 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. Total plasma clearance (the volume of plasma cleared of the drug over time) was calculated as: Clp = Dose/ AUC∞.
| mL/minute | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance |
|---|---|---|---|---|
| Total Plasma Clearance of Iohexol | 97.596 ± 22.6026 | 47.418 ± 19.9867 | 90.788 ± 25.7641 | 45.963 ± 19.1755 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The terminal rate constant (λz) was determined by linear regression of the terminal linear phase of the log plasma concentration-time profile.
| 1/minutes | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| The Terminal Rate Constant for MB-102 | 0.006 ± 0.0012 | 0.003 ± 0.001 | 0.005 ± 0.0009 | 0.003 ± 0.0012 | 0.006 ± 0.001 | 0.003 ± 0.0007 | 0.005 ± 0.0008 | 0.006 ± 0.0006 | 0.003 ± 0.0009 | 0.006 ± 0.0009 | 0.005 ± 0.0008 | 0.006 ± 0.0009 | 0.002 ± 0.0007 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. The terminal rate constant (λz) was determined by linear regression of the terminal linear phase of the log plasma concentration-time profile.
| 1/minutes | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance |
|---|---|---|---|---|
| The Terminal Rate Constant for Iohexol | 0.005 ± 0.001 | 0.002 ± 0.0009 | 0.005 ± 0.0009 | 0.002 ± 0.0008 |
Urine samples were collected pre-dose (time 0) and 5 mL urine samples were collected each time the subject voided. The total volume of urine excreted was recorded until 12 hours post-dose, and was analyzed using validated analytical methods. Renal clearance (the volume of plasma cleared of the drug by the kidneys over time) was calculated as: CLr = Ae/ AUClast, where Ae is the cumulative amount of analyte excreted in urine over the sampling interval.
| mL/minute | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Renal Clearance of MB-102 | 111.396 ± 27.9973 | 52.171 ± 21.825 | 104.008 ± 32.3622 | 51.915 ± 26.3905 | 105.144 ± 19.2031 | 45.397 ± 14.1766 | 99.072 ± 19.0079 | 120.452 ± 40.0937 | 42.51 ± 12.9745 | 109.924 ± 35.5733 | 88.795 ± 3.2184 | 103.774 ± 24.9108 | 38.373 ± 13.0747 |
Urine samples were collected pre-dose (time 0) and 5 mL urine samples were collected each time the subject voided. The total volume of urine excreted was recorded until 12 hours post-dose, and was analyzed using validated analytical methods. Renal clearance (the volume of plasma cleared of the drug by the kidneys over time) was calculated as: CLr = Ae/ AUClast, where Ae is the cumulative amount of analyte excreted in urine over the sampling interval.
| mL/minute | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance |
|---|---|---|---|---|
| Renal Clearance of Iohexol | 98.548 ± 22.5239 | 47.909 ± 20.1816 | 92.258 ± 26.5401 | 46.109 ± 19.4391 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and were analyzed using validated analytical methods. Transdermal fluorescence intensity at the time of blood sampling as measured by the QuantumLeap device was documented, and the correlation between the transdermal fluorescence intensity of MB-102 as measured by the QuantumLeap device and the plasma concentration of MB-102 at each time point in the renal excretion phase was calculated.
| Coefficient of determination, r-squared | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap |
|---|---|---|
| Correlation Between the Transdermal Fluorescence Intensity of MB-102 as Measured by the Quantum Leap Device and Plasma Concentration of MB-102 at Each Time Point in the Renal Excretion Phase | -0.999 ± 0.0009 | -0.998 ± 0.0028 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) minutes post dose, and will be analyzed using validated analytical methods. Transdermal fluorescence intensity at the time of blood sampling as measured by the Radiance device was documented, and the correlation between the transdermal fluorescence intensity of MB-102 as measured by the Radiance device and the plasma concentration of MB-102 at each time point in the renal excretion phase was calculated.
| Coefficient of determination, r-squared | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance |
|---|---|---|
| Correlation Between the Transdermal Fluorescence Intensity of MB-102 as Measured by the Radiance Device and Plasma Concentration of MB-102 at Each Time Point in the Renal Excretion Phase | -0.999 ± 0.001 | -0.998 ± 0.0033 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, and 480 minutes post dose, and were analyzed using validated analytical methods. Transdermal fluorescence intensity at the time of blood sampling as measured by the Brilliance device was documented, and the correlation between the transdermal fluorescence intensity of MB-102 as measured by the Brilliance device and the plasma concentration of MB-102 at each time point in the renal excretion phase was calculated.
| Coefficient of determination, r-squared | Normal-CKD Stage 2/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 |
|---|---|---|---|---|---|---|
| Correlation Between the Transdermal Fluorescence Intensity of MB-102 as Measured by the Brilliance Device and Plasma Concentration of MB-102 at Each Time Point in the Renal Excretion Phase in Participants With Normal-CKD Stage 2 Renal Function | -0.994 ± 0.0092 | -0.998 ± 0.0026 | -0.999 ± 0.0015 | -0.997 ± 0.0037 | -0.999 ± 0.0015 | -1 ± 0.0001 |
Blood samples were collected pre-dose (time 0) and at 5, 10, 15; (± 1 or 2 min), 30, 60, 90, 120, 180, 240, 300 (±5 min), 360, 480, 600 and 720 (±10 min) and 960, 1440, 1920, 2400, and 2880 (±30 min) minutes post dose, and were analyzed using validated analytical methods. Transdermal fluorescence intensity at the time of blood sampling as measured by the Brilliance device was documented, and the correlation between the transdermal fluorescence intensity of MB-102 as measured by the Brilliance device and the plasma concentration of MB-102 at each time point in the renal excretion phase was calculated.
| Coefficient of determination, r-squared | CKD Stage 3-5/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance 1-2 Sensors |
|---|---|---|---|
| Correlation Between the Transdermal Fluorescence Intensity of MB-102 as Measured by the Brilliance Device and Plasma Concentration of MB-102 at Each Time Point in the Renal Excretion Phase in Participants With CKD Stage 3-4 Renal Function | -0.999 ± 0.0015 | -0.998 ± 0.0018 | -0.993 ± 0.0193 |
The number of participants with adverse events related to the use of the QuantumLeap device was documented.
| Participants | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap |
|---|---|---|
| Number of Participants With Adverse Events Related to the Use of the QuantumLeap Device | 4 | 0 |
The number of participants with adverse events related to the use of the Radiance device was documented.
| Participants | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance |
|---|---|---|
| Number of Participants With Adverse Events Related to the Use of the Radiance Device | 1 | 0 |
The number of participants with adverse events related to the use of the Brilliance device was documented.
| Participants | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events Related to the Use of the Brilliance Device | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Treatment-emergent adverse events were collected from the time of dosing through the follow-up visit, up to 10 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Normal-CKD Stage 2/QuantumLeap | 0/31 (0%) | 0/31 (0%) | 7/31 (22.6%) |
| CKD Stage 3-4/QuantumLeap | 0/29 (0%) | 0/29 (0%) | 5/29 (17.2%) |
| Normal-CKD Stage 2/Radiance | 0/20 (0%) | 0/20 (0%) | 2/20 (10%) |
| CKD Stage 3-5/Radiance | 0/40 (0%) | 0/40 (0%) | 0/40 (0%) |
| Normal-CKD Stage 2/Brilliance Algorithm Optimization | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| CKD Stage 3-5/Brilliance Algorithm Optimization | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Normal-CKD Stage 2/Brilliance Sensor Optimization | 0/18 (0%) | 0/18 (0%) | 2/18 (11.1%) |
| Normal-CKD Stage 2/Brilliance Sensor Validation | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| CKD Stage 3-5/Brilliance Sensor Validation | 0/18 (0%) | 0/18 (0%) | 1/18 (5.6%) |
| Normal-CKD Stage 2/Brilliance (1-2 Sensors) | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| CKD Stage 3-5/Brilliance 1-2 Sensors | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Event | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site extravasationGeneral disorders | 0/31 | 0/29 | 0/20 | 0/40 | 0/9 | 0/7 | 0/18 | 0/30 | 1/18 | 2/12 | 1/4 | 1/4 | 1/12 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/31 | 0/29 | 0/20 | 0/40 | 0/9 | 0/7 | 0/18 | 0/30 | 0/18 | 0/12 | 0/4 | 1/4 | 0/12 |
| RashSkin and subcutaneous tissue disorders | 0/31 | 1/29 | 0/20 | 0/40 | 0/9 | 1/7 | 0/18 | 0/30 | 0/18 | 0/12 | 0/4 | 0/4 | 0/12 |
| Application site discolorationGeneral disorders | 0/31 | 0/29 | 0/20 | 0/40 | 0/9 | 0/7 | 2/18 | 0/30 | 0/18 | 0/12 | 0/4 | 0/4 | 0/12 |
| Hot flushVascular disorders | 0/31 | 0/29 | 0/20 | 0/40 | 1/9 | 0/7 | 0/18 | 0/30 | 0/18 | 0/12 | 0/4 | 0/4 | 0/12 |
| HeadacheNervous system disorders | 1/31 | 1/29 | 0/20 | 0/40 | 0/9 | 0/7 | 0/18 | 0/30 | 0/18 | 0/12 | 0/4 | 0/4 | 1/12 |
| Oedema peripheralGeneral disorders | 1/31 | 2/29 | 0/20 | 0/40 | 0/9 | 0/7 | 0/18 | 0/30 | 0/18 | 0/12 | 0/4 | 0/4 | 0/12 |
| NauseaGastrointestinal disorders | 2/31 | 0/29 | 0/20 | 0/40 | 0/9 | 0/7 | 0/18 | 0/30 | 0/18 | 0/12 | 0/4 | 0/4 | 0/12 |
| Application site erythemaGeneral disorders | 2/31 | 0/29 | 1/20 | 0/40 | 0/9 | 0/7 | 0/18 | 0/30 | 0/18 | 0/12 | 0/4 | 0/4 | 0/12 |
| Injection site bruisingGeneral disorders | 2/31 | 1/29 | 0/20 | 0/40 | 0/9 | 0/7 | 0/18 | 0/30 | 0/18 | 0/12 | 0/4 | 0/4 | 0/12 |
Safety Analysis Set: all participants who signed the informed consent form and received study drug
| Age, Continuous(years) | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 40.3 ± 11.78 | 58.2 ± 11.76 | 54.7 ± 13.57 | 61.1 ± 12.93 | 46.9 ± 13.40 | 66.9 ± 6.67 | 41.6 ± 15.42 | 39.1 ± 15.38 | 70.9 ± 8.09 | 47.9 ± 17.70 | 52.3 ± 14.27 | 42.5 ± 13.72 | 70.3 ± 9.46 | 53 ± 16.7 |
| Sex: Female, Male(Participants) | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 19 | 14 | 10 | 21 | 2 | 6 | 8 | 16 | 6 | 6 | 1 | 2 | 4 | 115 |
| Male | 12 | 15 | 10 | 19 | 7 | 1 | 10 | 14 | 12 | 6 | 3 | 2 | 8 | 119 |
| Race (NIH/OMB)(Participants) | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Asian | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 15 | 11 | 7 | 15 | 4 | 2 | 7 | 11 | 1 | 6 | 2 | 2 | 4 | 87 |
| White | 15 | 18 | 11 | 25 | 5 | 5 | 11 | 19 | 17 | 6 | 2 | 2 | 8 | 144 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Normal-CKD Stage 2/QuantumLeap | CKD Stage 3-4/QuantumLeap | Normal-CKD Stage 2/Radiance | CKD Stage 3-5/Radiance | Normal-CKD Stage 2/Brilliance Algorithm Optimization | CKD Stage 3-5/Brilliance Algorithm Optimization | Normal-CKD Stage 2/Brilliance Sensor Optimization | Normal-CKD Stage 2/Brilliance Sensor Validation | CKD Stage 3-5/Brilliance Sensor Validation | Normal-CKD Stage 2/Brilliance (1-2 Sensors) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) | Normal-CKD Stage 2/Brilliance (1-2 Sensors and Brilliance 2-part Sensor) and 2 Doses MB-102 | CKD Stage 3-5/Brilliance 1-2 Sensors | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 31 | 29 | 20 | 40 | 9 | 7 | 18 | 30 | 18 | 12 | 4 | 4 | 12 | 234 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2016 to primary completion in Aug 2021, 62 months.
Results were first posted in Oct 2023, 2 years 2 months after primary completion.
Of 57 phase 2 interventional studies under Acute Kidney Injury, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 42. This study's 62 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Relmapirazin · Iohexol
MediBeacon